Wockhardt Share Zooms 10% To 52 Week High After Company's Antibiotic 'Zaynich' Successfully Treated 73 Year Old Cancer Patient

Wockhardt's share price touched upper circuit level of 10 per on NSE (National Stock Exchange), after company's exchange filling, revealed, that their proprietary antibiotic named 'Zaynich' was succesful treated a 73 year old patient aling from chronic bile duct infection.

The Wockahardt's stock went on touch the 10 per cent upper circuit and day high level of Rs 1,536.60 per share on the Indian bourses after hitting the opening bell Rs 1,422.00 per share

Wockahrdt's shares were trading around Rs 1,522.50 per share on the NSE (National Stock Exchange), with a surge of 8.99 per cent amounting to a Rs 125.55 per share on the indian bourses.

Patient's diagnosis

The infection remained after more than six weeks of therapy with expensive antibiotics like cefiderocol and eravacycline, preventing a vital liver transplant.

Zaynich was recommended by the medical team under the US FDA's compassionate-use program.

According to a statement released by the Wockhardt on Monday, the patient was later able to have a liver transplant and was released from the hospital.

Pseudomonas aeruginosa and Klebsiella pneumoniae are among the widely drug-resistant organisms that caused the patient's sepsis, liver abscess, and cholangitis, according to the treating physician. These infections were particularly difficult to treat since they showed resistance mechanisms as IMP, NDM, and OXA-48.

Wockhardt's new antibiotic

Wockhardt created the new antibiotic Zaynich, which combines Zidebactam and Cefepime, to treat Gram-negative infections that are resistant to multiple drugs. The medication neutralises difficult resistance features by using a β-lactam enhancer mechanism. With intentions for worldwide commercial approval, it is presently undergoing Phase III studies.